NCT05231369View on ClinicalTrials.gov

Safety and Immunogenicity of ChulaCov19 BNA159 mRNA Vaccine

PHASE1UnknownINTERVENTIONAL
Enrollment

24

Participants

Timeline

Start Date

December 14, 2022

Primary Completion Date

July 1, 2023

Study Completion Date

July 1, 2023

Conditions
Safety of 25 ug of ChulaCov19-BNA159 mRNA VaccineTolerability of 25 ug of ChulaCov19-BNA159 mRNA VaccineImmune Response of 25 ug of ChulaCov19-BNA159 mRNA VaccineSafety of 50 ug of ChulaCov19-BNA159 mRNA VaccineTolerability of 50 ug of ChulaCov19-BNA159 mRNA VaccineImmune Response of 50 ug of ChulaCov19-BNA159 mRNA VaccineAssess Which Dose is Appropriate to Use
Interventions
BIOLOGICAL

ChulaCov19 BNA159 mRNA vaccine

ChulaCov19 BNA159 mRNA vaccine is the lipid nanoparticles (LNPs)-encapsulated mRNA-based ChulaCov19 vaccine

Trial Locations (2)

10330

RECRUITING

Chula Clinical Research Center (Chula CRC), Faculty of Medicine, Chulalongkorn University, Bangkok

Unknown

RECRUITING

Academic Clinical Research Office (ACRO) Faculty of Medicine, Khon Kaen University, Khon Kaen

Sponsors

Collaborators (1)

BioNet-Asia
All Listed Sponsors
collaborator

Chula Clinical Research Center (Chula CRC), Faculty of Medicine, Chulalongkorn University

UNKNOWN

collaborator

Academic Clinical Research Office (ACRO), Faculty of Medicine, Khon Kaen University

UNKNOWN

collaborator

BioNet-Asia

UNKNOWN

lead

Chulalongkorn University

OTHER